PARK7 and cancer: DMF has been found to target a range of pathways involved in cancer pathogenesis to achieve antitumor efficacy, including nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2), protein deglycase DJ-1/Parkinson disease protein 7 (DJ-1), and extracellular signal-regulated kinase 1 and 2 (ERK1/2) (27).